Bellicum Pharmacueticals Inc. (BLCM) Trading Down 5.4%
Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) dropped 5.4% during mid-day trading on Wednesday . The stock traded as low as $17.29 and last traded at $17.61, with a volume of 237,031 shares. The stock had previously closed at $18.61.
BLCM has been the topic of several recent research reports. Citigroup Inc. raised shares of Bellicum Pharmacueticals from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Tuesday, August 9th. Jefferies Group lifted their target price on shares of Bellicum Pharmacueticals from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, August 9th. SunTrust Banks Inc. initiated coverage on shares of Bellicum Pharmacueticals in a research note on Thursday, June 2nd. They set a “buy” rating and a $20.00 target price on the stock. Zacks Investment Research cut shares of Bellicum Pharmacueticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 11th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $31.00 target price (up previously from $25.00) on shares of Bellicum Pharmacueticals in a research note on Tuesday, August 9th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Bellicum Pharmacueticals currently has a consensus rating of “Buy” and a consensus target price of $27.00.
The stock’s market cap is $464.96 million. The firm’s 50-day moving average is $16.27 and its 200 day moving average is $12.02.
Bellicum Pharmacueticals (NASDAQ:BLCM) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by $0.04. During the same period in the previous year, the business earned ($0.40) earnings per share. Equities analysts expect that Bellicum Pharmacueticals Inc. will post ($2.32) earnings per share for the current year.
In other Bellicum Pharmacueticals news, COO Annemarie Moseley sold 25,000 shares of the stock in a transaction on Thursday, June 2nd. The stock was sold at an average price of $13.00, for a total value of $325,000.00. Following the completion of the transaction, the chief operating officer now owns 18,486 shares in the company, valued at $240,318. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CTO Kevin M. Slawin sold 2,719 shares of the stock in a transaction on Monday, July 18th. The stock was sold at an average price of $13.99, for a total value of $38,038.81. Following the completion of the transaction, the chief technology officer now owns 134,206 shares of the company’s stock, valued at approximately $1,877,541.94. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in Bellicum Pharmacueticals stock. Morgan Stanley raised its stake in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned approximately 1.61% of Bellicum Pharmacueticals worth $8,653,000 at the end of the most recent reporting period.
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.